Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07266285 · ClinicalTrials.gov registry record · Phase 1

BTM-3566 in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Bantam Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT07266285 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Bantam Pharmaceuticals. The registered enrollment target is 30 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07266285, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Bantam Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to learn about what doses of BTM-356 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of BTM-3566 are in treating cancer. The main questions it aims to answer are: What adverse events and toxicities (harmful side effects) are associated with different doses of BTM-3566? What are the blood levels of BTM-3566 in your body at different timepoints? What effect does BTM-3566 have on reducing tumor size and/or preventing the worsening of cancer? All participants will receive BTM-3566 and none will receive placebo (a look-alike substance that contains no drug). Participants will: * Take BTM-3566 for 7 days, then take a 7 day break. This 2 week dosing schedule of 7 days on/7 days off will continue until your disease worsens or you cannot tolerate treatment. * Visit the clinic approximately 7 times during screening and the first month of treatment. Visits will be reduced to approximately 2 visits per month after. * Keep a diary of when (and how much) BTM-3566 you take, along with how much you weigh on each dosing day.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG BTM-3566

Study Locations (2)

Texas

  • NEXT Houston - Houston
  • NEXT Oncology - San Antonio

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-12-10
Est. Completion 2027-08
Phase Phase 1

Sponsor

Bantam Pharmaceuticals

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07266285

The ClinicalTrials.gov registry entry for NCT07266285 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (85% lower). The listed sponsor is Bantam Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which BTM-3566 is the first listed.

NCT07266285 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT07266285 about?

NCT07266285 is a clinical study titled "BTM-3566 in Advanced Solid Tumors". The goal of this clinical trial is to learn about what doses of BTM-356 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of BTM-3566 are in treating cancer. The main questions it aims to answer are: What adverse events and toxic...

What is the current status of trial NCT07266285?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-12-10. Estimated completion is 2027-08.

What conditions does trial NCT07266285 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT07266285?

The interventions under investigation include: BTM-3566 (DRUG).

Who is sponsoring clinical trial NCT07266285?

This trial is sponsored by Bantam Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07266285 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.